YOLFTbeta
ProKidney Corp.

ProKidney Corp.

PROK · NASDAQ · Healthcare / Biotechnology

1.05USD-0.10 (-9.13%)

Price History

Full chart

Market Stats

Previous Close1.15
Open1.16
Day Range1.02 – 1.16
52-Week Range1.30 – 3.48
Volume1.29M
Market Cap638.69M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.55
Dividend Yield0.00%
Beta1.75
50-Day Avg1.67
200-Day Avg1.91

About

ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Bruce Culleton M.D.
  • Employees231
  • Headquarters2000 Frontis Plaza Boulevard, Winston-Salem, NC, United States, 27103, USA
  • Websitehttps://prokidney.com

Leadership

  • Dr. Bruce Culleton M.D.CEO & Director · b. 1969
  • Mr. James Coulston CPAChief Financial Officer · b. 1977
  • Mr. Todd C. Girolamo Esq., J.D., M.B.A.Chief Legal Officer & Secretary · b. 1965
  • Mr. Kenneth LockeChief Technical Officer
  • Mr. Richard WilliamsChief Information Officer
  • Ms. Carla PoulsonChief People Officer
  • Dr. Joseph M. Stavas M.D., M.P.H.Senior Vice President of Interventional Procedures
  • Dr. Darin J. Weber Ph.D.Chief Reg. Off, SVP and Head of Global Reg. Affairs, Quality Mgmt, Biometrics & Market Access · b. 1968
  • Dr. Emily Butler Ph.D.Senior VP of Biometric
  • Mr. Gregory P. MadisonChief Commercial Officer · b. 1967

Financials

Income Statement

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue-000076.00K893.00K
Growth (%)------+1075.00%
Cost of Revenue--1.98M3.04M3.17M-5.72M
Gross Profit---1.98M-3.04M-3.17M76.00K893.00K
Gross Margin-----100.00%100.00%
Operating Expense--53.13M149.97M148.35M183.75M165.90M
Operating Income-79.38M-27.02M-55.11M-153.01M-151.52M-183.68M-165.01M
Operating Margin------241678.95%-18477.83%
EBITDA-18.29M-26.06M-53.12M-143.99M-125.59M-158.49M-144.62M
EBITDA Margin------208542.11%-16194.74%
Net Income-79.61M-26.75M-55.15M-108.03M-35.47M-61.19M-68.99M
Net Income Margin------80507.89%-7725.20%
R&D75.22M21.04M46.26M82.07M106.71M127.67M114.12M
R&D as % of Total Revenue-----167984.21%12779.73%
Interest Expense043.00K2.00K215.00K12.00K9.00K4.00K
Interest Expense % of Total Revenue-----11.84%0.45%

Balance Sheet

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets19.61M16.70M40.30M518.00M420.55M441.07M335.57M
Total Liabilities3.72M6.84M13.38M13.06M29.22M39.44M34.78M
Total Equity15.88M9.86M26.92M-1.10B-1.10B-994.95M-1.01B
Cash15.23M4.58M20.56M490.25M60.65M99.12M108.54M
Total Debt1.11M1.56M1.33M2.40M4.41M3.24M4.04M
Net Debt-14.11M-3.02M-19.22M-487.85M-56.24M-95.88M-104.50M

Cash Flow

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-76.81K-25.18M-50.30M-77.09M-90.07M-126.35M-120.12M
Investing Cash Flow-2.97K-5.46M-5.19M-1.74M-329.98M20.41M103.97M
Financing Cash Flow20.00K19.99M71.47M548.52M-9.55M144.41M25.57M
Capital Expenditure1.30K5.46M5.19M1.85M34.20M29.51M15.20M
Free Cash Flow-78.11K-30.64M-55.49M-78.94M-124.27M-155.86M-135.31M
FCF to OCF101.70%121.67%110.32%102.39%137.97%123.35%112.65%

Earnings

Report DateJun 9, 2021Aug 16, 2021Nov 15, 2021Mar 24, 2022May 16, 2022Aug 12, 2022Nov 14, 2022Mar 28, 2023May 11, 2023Aug 10, 2023Nov 14, 2023Mar 22, 2024May 10, 2024Aug 9, 2024Nov 12, 2024Mar 17, 2025May 12, 2025Aug 12, 2025Nov 10, 2025Mar 18, 2026May 15, 2026Aug 10, 2026Nov 9, 2026
EPS Estimate0.00-----0.06-0.31-0.24-0.12-0.41-0.14-0.17-0.18-0.18-0.22-0.15-0.16-0.14-0.14-0.15-0.14-0.13-0.12
EPS Actual0.00-0.01-0.01-0.06-0.12-0.06-0.13-0.11-0.16-0.14-0.18-0.09-0.16-0.16-0.14-0.17-0.13-0.13-0.12-0.14-0.14-0.15-
Surprise-----7.00%58.06%54.17%-33.33%65.85%-28.57%47.06%11.11%11.11%36.36%-13.33%18.75%7.14%14.29%6.67%-1.82%-15.38%-
Timing---After-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursPre-marketPre-marketPre-market-After-hoursAfter-hoursAfter-hours-After-hoursAfter-hours

Key Statistics & Ratios

Market Cap638.69M
Enterprise Value204.30M
Trailing P/E0.00
Forward P/E0.00
Price / Sales780.80
Price / Book97.15
EPS-0.55
Book Value-4.30
Revenue (TTM)818.00K
Gross Profit (TTM)818.00K
EBITDA-170.37M
Profit Margin0.00%
Operating Margin-32248.67%
Return on Equity-58.96%
Return on Assets-35.66%
Shares Outstanding208.93M
Shares Float184.65M
Beta1.75
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 7 analystsTarget 6.25
  • Strong Buy
    4
  • Hold
    3

Ownership Breakdown

Institutions
26.37%
Insiders
46.45%
Retail / Other
27.18%

Top Institutional Holders

  • Suvretta Capital Management, LLC
    12.34M5.91%
  • Morgan Stanley - Brokerage Accounts
    8.96M4.29%
  • Bleichroeder LP
    2.00M0.96%
  • Hennion & Walsh Asset Management Inc
    1.85M0.88%
  • Artia Global Partners LP
    1.81M0.86%
  • BlackRock Inc
    1.39M0.66%
  • Renaissance Technologies Corp
    1.25M0.60%
  • Geode Capital Management, LLC
    1.23M0.59%
  • Vanguard Capital Management, LLC
    1.15M0.55%
  • Millennium Management LLC
    1.05M0.50%
  • Marshall Wace Asset Management Ltd
    1.01M0.48%
  • Bank of America Corp
    753.41K0.36%

Top Fund Holders

  • NUMC B0-B
    3.43M1.64%
  • iShares Russell 2000 ETF
    1.70M0.81%
  • Morgan Stanley Insight I
    1.12M0.54%
  • BrighthouseI Morgan Stanley Discovery B
    1.08M0.52%
  • GBM104 A
    1.00M0.48%
  • Morgan Stanley Inst Discovery I
    820.88K0.39%
  • Fidelity Small Cap Index
    781.63K0.37%
  • GBM103 A
    750.00K0.36%